Skip to content

Novel Serum Markers for Monitoring Response to Anti-Cancer Therapy

Development of Novel Serum Markers for Monitoring Response to Anti-Cancer Therapy

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT00349830
Enrollment
2000
Registered
2006-07-10
Start date
2002-01-01
Completion date
2032-01-01
Last updated
2026-02-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Carcinomas (Including Squamous Cell and Adenocarcinoma), Neoplasms

Brief summary

The purpose of this study is to measure the levels of serum proteins and other biomarkers in cancer patients and in patients suspected of having cancer. We believe that some of these markers may be useful for confirming the diagnosis or for selecting patients for specific types of cancer therapies. These markers may also help to predict response to therapy, relapse after therapy, and survival after therapy.

Detailed description

This is a blood serum collection study at Stanford University for patients with cancer at a variety of disease sites. The purpose of this study is to collect and store blood serum from patients before, during, and after anti-cancer therapy to find new biomarkers that signal disease or response to anti-cancer therapy. The collection and analysis of these biomarkers may lead to improved diagnostic and treatment therapies for certain cancers in the future. We are also interested in collecting blood serum from healthy individuals such as the spouses, relatives, and friends of cancer patients to obtain healthy controls for comparison

Interventions

PROCEDUREblood draw

Sponsors

Stanford University
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

1. Age \> or = 18; for the samples collected under the NIH grant, no subjects below the age of 20 will be enrolled. 2. Prior diagnosis of cancer or suspected of having cancer 3. Karnofsky performance status of greater than 70 4. Standard pretreatment evaluation 5. Signed Stanford University Human Subjects Committee consent

Design outcomes

Primary

MeasureTime frame
Biomarkers for diseaseDay one

Countries

United States

Contacts

CONTACTgitrialeligibility@stanford.edu gitrialeligibility@stanford.edu
gitrialeligibility@stanford.edu650-498-7757
CONTACTgitrialeligibility@stanford.edu
gitrialeligibility@stanford.edu650-498-7757
PRINCIPAL_INVESTIGATORMaximilian Diehn

Stanford University

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 11, 2026